Q2 2023 National Research Corporation Earnings Call

Okay.

Hello, and welcome to today's National Research Corporation second quarter 2023 earnings call. My name is Bailey and OBO module ratios day, all lines will be muted during the presentation posted the cold, but an opportunity for questions at the end. If you would like to ask a question. Please press star followed by one on your telephone keypad.

Yeah.

I'd now like to pass the conference over to Kevin <unk>, Chief Financial Officer. Please go ahead.

Thank you Billy and welcome everyone to National Research Corporation's 2023 second quarter earnings call.

My name is Kevin tariffs, the Companys CFO and joining me on the call today is when to Stacy <unk> Vice President of finance.

Before we continue I'd like to ask Linda to review conditions related to any forward looking statements that may be made as part of today's call. Linda. Thank you. Kevin. This conference call includes forward looking statements related to the company that involve risks and uncertainties that could cause actual results or outcomes to differ materially.

Or at least from those currently anticipated. These forward looking statements are made pursuant to the safe Harbor provisions of the private Securities Litigation Reform Act of 1985 for further information about the facts that could affect the company's future results. Please see the company's filings with the Securities and Exchange Commission with that I'll turn it back to you Kevin.

Thanks, Linda and again welcome everyone.

Over the past several quarters, we have significantly expanded our sales force and marketing spend focused on supporting the rollout of our human understanding program.

While it is early days the material expansion of sales and marketing resources has been very effective in building a stronger sales pipeline and in the second quarter of 2023, we gained momentum in converting opportunities, which resulted in a 53% increase in new sales compared to the second quarter of 2022.

Two.

Okay.

Day, one third of our human understanding program clients are from new logos.

With two thirds, representing adoption of the program from current partner organizations.

Contract value growth for human understanding program adoption by existing clients.

Then 12%, which.

Which is in line with results from the successful rollout of our real time solutions several years ago.

Let me turn the call back over to Linda to review, our financial performance and then open the call for questions. Thank you Kevin revenue for the second quarter 2023 decreased compared to the second quarter of 2022 by 3% partially attributed to the closure of our Canadian operations and discontinuation of other noncore solution.

<unk>.

We ended the quarter with $146 6 million in Trc D, including a 1% increase in Trc D for our core solutions. Our Trc metric represents the total revenue projected under all renewable contracts for their respective next annual renewal periods.

Upsell stem cells price increases are cancellations measured as of the most recent quarter end.

Operating income decreased by 19% for the second quarter of 2023 compared to the second quarter of 2022, primarily due to the decline in revenue and growth in marketing expenses of 906000 to expand brand recognition and support sales development.

We have been focusing on the alignment of our cost structure with business requirements and the results were positive this quarter, although we increased spending per sales and marketing expansion, we were able to reduce consolidated operating expenses, resulting in a two 4% gross margin and a one 2% operating income margin improvement in the second.

Quarter as compared to the first quarter of 2023.

We are implementing other cost alignment changes that will enable continued quarterly margin improvement in future quarters. The.

The effective tax rate in the second quarter of 2023 was 23% compared to 25% in 2022, primarily due to increased tax benefits from the exercise of share based compensation awards.

The Companys board of directors maintained its capital allocation priorities of funding innovation and growth investments, including merger and acquisition activity as well as internal projects shareholder dividends and share repurchases during 2023.

In the second quarter of 2023, the company funded $4 2 million for innovation and growth 3 million for dividend payments and $1 8 million for share repurchases.

That concludes my comments for this morning, I'll now turn the call back to you Kevin.

This completes our prepared remarks, so bailey I will ask you to open the call to any questions.

Thank you.

I would like to ask a question. Please press star followed by one on your telephone keypad. If for any reason you would like to meet that question. Please press star followed by cheap again to ask a question. Please press star followed by one.

If you are using a speaker phone. Please remember to pick up your handset before asking your question I'm pleased to ensure that you have understood locally.

As a reminder, if you would like to ask a question. Please press star followed by one.

There are currently no register your questions. So I'd like to pass the call back to the management team for any closing remarks.

Thank you.

We'd like to close by thanking everyone for your time today, and we look forward to sharing our results again next quarter.

This concludes today's conference call. Thank you for your participation you may now disconnect your line.

[music].

Okay.

Thank you.

Okay.

This concludes today's conference call. Thank you for your participation you may now disconnect your lines.